Wall Street brokerages predict that Aerie Pharmaceuticals Inc (NASDAQ:AERI) will report earnings per share (EPS) of ($0.74) for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Aerie Pharmaceuticals’ earnings, with estimates ranging from ($0.84) to ($0.63). Aerie Pharmaceuticals posted earnings per share of ($0.87) during the same quarter last year, which would suggest a positive year-over-year growth rate of 14.9%. The company is scheduled to issue its next earnings results on Wednesday, August 2nd.
According to Zacks, analysts expect that Aerie Pharmaceuticals will report full year earnings of ($2.98) per share for the current year, with EPS estimates ranging from ($3.26) to ($2.45). For the next year, analysts expect that the company will post earnings of ($2.60) per share, with EPS estimates ranging from ($2.94) to ($2.12). Zacks’ EPS calculations are a mean average based on a survey of research analysts that follow Aerie Pharmaceuticals.
Aerie Pharmaceuticals (NASDAQ:AERI) last posted its quarterly earnings results on Tuesday, May 2nd. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by $0.02.
A number of research firms have weighed in on AERI. HC Wainwright restated a “buy” rating and set a $69.00 price target on shares of Aerie Pharmaceuticals in a research report on Wednesday, May 3rd. Raymond James Financial, Inc. downgraded Aerie Pharmaceuticals from a “strong-buy” rating to a “market perform” rating and set a $48.00 price target on the stock. in a research report on Thursday, March 9th. They noted that the move was a valuation call. Aegis restated an “in-line” rating and set a $63.00 price target on shares of Aerie Pharmaceuticals in a research report on Wednesday, March 8th. Cowen and Company began coverage on Aerie Pharmaceuticals in a research report on Friday, February 24th. They set an “outperform” rating and a $70.00 price target on the stock. Finally, Canaccord Genuity set a $50.00 price target on Aerie Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, March 1st. Two equities research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. Aerie Pharmaceuticals has an average rating of “Buy” and an average target price of $57.62.
WARNING: “Aerie Pharmaceuticals Inc (AERI) Expected to Post Earnings of -$0.74 Per Share” was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://sportsperspectives.com/2017/05/19/aerie-pharmaceuticals-inc-aeri-expected-to-post-earnings-of-0-74-per-share-updated.html.
In other news, Director Geoffrey M. Duyk sold 41,591 shares of Aerie Pharmaceuticals stock in a transaction dated Wednesday, February 15th. The stock was sold at an average price of $46.63, for a total value of $1,939,388.33. Following the transaction, the director now owns 10,067 shares in the company, valued at $469,424.21. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, Director Gerald D. Cagle acquired 2,000 shares of the firm’s stock in a transaction dated Wednesday, April 19th. The stock was bought at an average price of $41.70 per share, for a total transaction of $83,400.00. Following the acquisition, the director now owns 10,900 shares of the company’s stock, valued at approximately $454,530. The disclosure for this purchase can be found here. 8.77% of the stock is currently owned by insiders.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in AERI. Federated Investors Inc. PA increased its position in Aerie Pharmaceuticals by 88.7% in the fourth quarter. Federated Investors Inc. PA now owns 4,447 shares of the company’s stock valued at $168,000 after buying an additional 2,090 shares in the last quarter. Karp Capital Management Corp bought a new position in Aerie Pharmaceuticals during the first quarter valued at approximately $213,000. First Mercantile Trust Co. increased its position in Aerie Pharmaceuticals by 29.9% in the first quarter. First Mercantile Trust Co. now owns 7,031 shares of the company’s stock valued at $319,000 after buying an additional 1,620 shares in the last quarter. DIAM Co. Ltd. bought a new position in Aerie Pharmaceuticals during the third quarter valued at approximately $294,000. Finally, Fox Run Management L.L.C. increased its position in Aerie Pharmaceuticals by 49.3% in the first quarter. Fox Run Management L.L.C. now owns 9,558 shares of the company’s stock valued at $433,000 after buying an additional 3,158 shares in the last quarter. Hedge funds and other institutional investors own 95.69% of the company’s stock.
Aerie Pharmaceuticals (NASDAQ:AERI) opened at 40.15 on Tuesday. The firm’s market cap is $1.35 billion. Aerie Pharmaceuticals has a 12-month low of $12.56 and a 12-month high of $51.85. The stock’s 50 day moving average price is $43.68 and its 200-day moving average price is $41.61.
Aerie Pharmaceuticals Company Profile
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aerie Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.